Eberkinase

According to statistics, among all known diseases, the most unfavorable prognosis is characterized by circulatory system disorders and oncological formations.

Pathologies of the circulatory system are often associated with a violation of the hemorheological parameters of the blood. In the treatment of this type of disorder, the drug Eberkinase is sometimes used - a fibrinolytic agent capable of dissolving intravascular thrombi.

Indications Eberkinase

Indications for use of the drug may be:

• emergency treatment of acute myocardial infarction (initial 6-48 hours);
• treatment of pulmonary embolism and its branches;
• any stage of thrombosis of arterial trunks of all localizations;
• formation of blood clots as a result of treatment and diagnostic measures in pediatrics (catheterization, hemodialysis bypass, heart valve replacement);
• chronic stage of obliterating endarteritis;
• chronic stage of arterial occlusion;
• recurrent thrombus formation after thrombectomy surgery;
• in thrombosis of the central vein and artery of the retina;
• acute form of deep vein thrombosis in the extremities and internal organs;
• cleaning catheters for intravenous administration of blood products;
• independent or combined therapy of ischemic heart disease.

Release form

It is produced in the form of a powder substance of 750 thousand FU or 1,500,000 FU in sealed bottles with a volume of 10 ml.

Pharmacodynamics

The active substance of the drug combines with plasminogen in stoichiometric proportions of 1:1, which favors the transition of plasminogen molecules into plasmin. The latter, in turn, is capable of dissolving fibrin fibers from blood clots and thrombi, as well as provoking a decrease in the functions of fibrinogen and other plasma proteins that participate in blood clotting.

Due to the properties of Eberkinase to effectively dissolve blood clots over their entire surface, as well as to restore the lumen of blood vessels and activate blood circulation in them, the use of the drug has made it possible to significantly reduce the number of fatal cases in myocardial infarction and pulmonary embolism.

Pharmacokinetics

The maximum concentration of the drug is observed already in the first 45 minutes. After the infusion administration is completed, the fibrinolysis effect can persist for several hours; thrombin time is extended during the day. The effect of a single dose lasts from 48 to 72 hours, the effect of thrombolysis (thromborolysis) is actively supplemented by fibrinogen cleavage processes.

Biotransformation occurs in the liver by hydrolysis (no identification data on metabolites).

The main amount of the active substance is broken down into peptides and excreted through the urinary system.

Dosing and administration

The powder substance is diluted in 5 ml of water for injection: all actions are carried out with caution, preventing the formation of foam in the solution. The resulting concentrate is transferred to a bottle with saline or 5% dextrose solution for intravenous drip infusion. The dosage and number of injections is determined by the doctor on an individual basis.

• In acute myocardial infarction, the drug is administered intravenously or intracardiacly. Complex treatment includes the introduction of Eberkinase into a peripheral vein at a dosage of 1.5 million FU over the course of one hour. Intracardiac administration is carried out using a coronary catheter: 20 thousand FU are used, simultaneously also carrying out intravenous administration.
• In case of venous thrombosis, the drug is used for intravenous administration using a catheter. The administration is carried out into the inguinal vein, subclavian vein, or into the vein of the lower leg. The drug is administered as early as possible from the moment of thrombus formation; the dosage is selected depending on the size and degree of resorption of the thrombus.
• In case of pulmonary embolism, 250 thousand FU of the drug are administered intravenously over half an hour. It may be necessary to administer the drug again.

Heparin may be prescribed as a preventive measure against recurrent thrombosis.

[ 2 ]

Use Eberkinase during pregnancy

The use of this fibrinolytic drug is contraindicated in the first half of pregnancy due to the fact that it can promote fibrin (fibrinoid) deposits at the edges of the trophoblast villi and disorders of postimplantation development of the embryo.

During the second half of pregnancy, the drug is used only according to absolute indications.

According to some experimental data, the active substance of the drug does not penetrate the placental barrier, so the dosage in the second half of pregnancy can be standard.

Contraindications

Among the main contraindications to the use of the drug are the following:

• allergic sensitivity to any component of Eberkinase;
• tendency to bleeding;
• confirmed data on the presence of hemorrhagic diathesis;
• erosions and ulcers of the digestive tract;
• inflammatory processes in the intestines;
• fresh open and closed wounds, bruises, fractures;
• aneurysms;
• neoplasms with the effect of growth into vascular tissue;
• brain cancer or metastatic lesions;
• chronic and severe cases of hypertension;
• vascular wall disorders in diabetes mellitus;
• inflammatory diseases of the endocardium and pericardium;
• mitral valve defect, atrial flutter;
• open form of tuberculosis;
• cavernous lung disease;
• septic conditions;
• rehabilitation period after open surgeries;
• recent internal biopsy;
• 90-day period after cerebral hemorrhage;
• first half of pregnancy;
• ten-day postpartum period;
• 2 weeks after artificial abortion;
• presence of permanent catheterization;
• liver cirrhosis, significant atherosclerosis;
• acute appendicitis.

Administration of the drug during treatment with other fibrinolytic agents during the last year is not recommended.

Side effects Eberkinase

Among the side effects during the period of taking the drug, the most common are bleeding:

• from any damaged areas of tissue and mucous membranes (gums, digestive tract, genitourinary system);
• spleen damage;
• various types of hemorrhages, including intradermal, intramuscular, and cerebral;
• the appearance of arrhythmia;
• phenomena of pulmonary edema with intracardiac administration of the drug;
• thrombus detachment;
• increased erythrocyte sedimentation rate;
• anaphylaxis when the drug is administered too intensively;
• dyspeptic symptoms, the possibility of developing allergic reactions up to anaphylactic shock.

[ 1 ]

Overdose

Symptoms of overdose may include increased severity of side effects and the appearance of multiple or single bleeding.

Therapeutic methods for overdose are limited to stopping the bleeding (if possible), prescribing antifibrinolytic drugs, and compensating for blood loss. Symptomatic therapy is administered if necessary.

A mandatory condition for the treatment of overdose is the complete discontinuation of the drug Eberkinase.

Interactions with other drugs

The inhibition of blood coagulation properties and the increased risk of hemorrhage are enhanced by the simultaneous use of Eberkinase with heparin, indirect anticoagulants (neodicoumarin, syncoumar, escusan), pyrimidine derivatives, and acetylsalicylic acid preparations.

It is not recommended to combine the administration of Eberkinase and plasma-substituting solutions.

[ 3 ], [ 4 ]

Storage conditions

The drug should be stored in the refrigerator. The optimal storage temperature is from 2 to 8 degrees. Children's access to the drug should be limited.

Shelf life

Eberkinase expiration date:

• bottle 1.5 million FU – up to 2 years;
• bottle 750 thousand FU – up to 3 years.

[ 5 ]